Key Takeaways INSP reported positive Inspire V data with enhanced safety and better patient adherence.INSP's trials showed 20% shorter surgical times and superior AHI improvement versus Inspire IV.INSP's U.S. release confirmed efficient implantation, stable therapy use and no serious adverse events. Inspire Medical Systems (INSP) recently unveiled promising clinical data from its Inspire V system at the ISSS and AAO-HNS meetings, showcasing strong safety, enhanced respiratory sensing and improved patient ad ...

Key Takeaways BDX enrolled the first patient in the XTRACT Registry to evaluate the Rotarex Catheter System for PAD.BDX's Rotarex system combines atherectomy and thrombectomy functions to treat PAD lesions effectively.BD aims to boost its PI business and improve patient outcomes through real-world evidence from the registry.Becton, Dickinson and Company (BDX) , popularly known as BD, announced the enrollment of the first patient in the XTRACT Registry. It is a prospective, multi-center, single-arm, post-mar ...

Valued at a market cap of $25.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. The San Diego, California-based company’s products help patients, caregivers, and healthcare professionals manage diabetes and broader metabolic health conditions in real time. It is expected to announce its fiscal Q3 earnings for 2025 after the market closes on Thursday, Oct. 30. Before this event, analysts expect this medical dev ...

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.30 per share, up from $1.21 per share in the year-ago period. Abbott Laboratories projects quarterly revenue of $11.4 billion, compared to $10.63 billion a year earlier, according to data from Benzinga Pro.On Sept. 19, the company's board of directors declared a quarterly common dividend ...

With a market cap of $18.8 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company that designs, manufactures, and markets innovative orthopedic reconstructive products, sports medicine solutions, biologics, and surgical technologies. The company serves healthcare professionals worldwide with advanced products that treat disorders and injuries of bones, joints, and soft tissues. The Warsaw, Indiana-based company is slated to announce its fiscal Q3 2025 results before the market ...

Key Takeaways Q3 MedTech growth at J&J should have been driven by strength in Cardiovascular and Surgery.New products and acquired units, Abiomed and Shockwave, are expected to have fueled further sales momentum.VBP impacts in China might have restrained J&J's MedTech profit performance in Q3.Johnson & Johnson's (JNJ) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.I ...

Key Takeaways PLSE reports encouraging feasibility results for its nPulse Cardiac Surgical System using nsPFA.PLSE study achieved 94% pulmonary vein and 100% posterior box isolation success with no major complications.An IDE study in the U.S. is planned, advancing PLSE toward regulatory approval and commercialization.Pulse Biosciences (PLSE) recently reported encouraging late-breaking data from the first-in-human feasibility study of its nPulse Cardiac Surgical System. The study data were unveiled at the 39 ...

ProSense® and IceCure received a high level of interest during a cryoablation faculty led by Dr. Richard Fine, a leading investigator of IceCure's ICE3 trail, the largest cryoablation study of its kind in the U.S. Dr. Fine is winner of the 2024 American Society of Breast Surgeons' Scientific Impact Award for his presentation of the ICE3 trial data and lead author of an ICE3 study published in the Annals of Surgical Oncology. IceCure delivered a product showcase presentation focused on ProSense®'s current ca ...

Initial Commercialization Targeting $732 Million Wound Care Market is Expected in Late 2025 or Early 2026 WESTMINSTER, CALIFORNIA / ACCESS Newswire / October 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that creates and commercializes sustainable technologies, today announced that its subsidiary Clyra Medical Technologies has achieved noteworthy progress across product development, commercialization, and clinical programs, advancing toward multiple near-term market launches and internationa ...

Core Insights - Apyx Medical Corporation has initiated the nationwide commercial launch of the AYON Body Contouring System, with a focus on expanding its capabilities to include power liposuction through a new 510(k) premarket notification to the FDA [2][3] - The AYON system is designed to integrate various body contouring procedures into a single platform, enhancing workflow for surgeons and potentially improving patient outcomes [3][5] - Apyx Medical is hosting a virtual event on October 14, 2025, featuring key opinion leaders to discuss the commercial launch and advancements of the AYON system [4] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with products like Renuvion and the AYON Body Contouring System [5] - The AYON Body Contouring System is FDA-cleared and combines multiple functionalities, including fat removal and tissue contraction, aimed at providing comprehensive body contouring treatments [5] - The company has received positive feedback from early adopters of the AYON system, indicating strong market interest and potential for growth [3]